French University Hospital starts a clinical trial of Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection
The University Hospital, Strasbourg, France is commencing recruitment for the clinical trial of the Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection.
The condition is Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment.
A new clinical trial is recruiting patients in the following locations: France.
The trial officially began on the January 18, 2021 and is planned to complete on May 24, 2021.
Diabetes is a major factor of morbi-mortality in Covid-19 infection. Currently, steroid therapy is required in patients under oxygen therapy. This treatment is associated with hyper glycaemia in patients with diabetes. Recommendations for the management of diabetes during Covid-19 infection is to use insulin treatment. The majority of units involves in the management of patient with Covid19 infection are not the experience in managing intensive insulin therapy and the time to ensure this follow-up. All the data in the literature are in favor of a positive impact of telemedicine on the metabolic control of diabetic patients. However, the routine use of telemedicine and more particularly tele-expertise within hospital units is very underdeveloped in France. The epidemic of Covid-19 represents a unique situation where the health authorities recommend to physicians to use telemedicine to ensure the follow-up and optimal management of patients. The aim of this study was to compare the metabolic control of diabetic patients infected with Covid-19 followed in tele-expertise to a group of diabetic patients infected with Covid-19 managed in standard conditions.
The population that can be enrolled into this study includes:
- Patients adult hospitalized for Covid-19 infection in the Infectious Diseases Department of the University Hospital of Strasbourg (HUS)
- Patients requiring steroid treatment
- Diabetic patients (type 1,2, MODY, secondary) or with corticosteroid-induced diabetes following initiation of corticosteroid treatment
Patients with the following conditions:
- Contraindication to the use of the Free-Style Medical Device
are excluded from participation.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04726163
